# Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

> **NCT06066580** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Edgewise Therapeutics, Inc.** · enrollment: 260 (estimated)

## Conditions studied

- Becker Muscular Dystrophy

## Interventions

- **DRUG:** Sevasemten

## Key facts

- **NCT ID:** NCT06066580
- **Lead sponsor:** Edgewise Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-11-02
- **Primary completion:** 2031-02
- **Final completion:** 2031-02
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06066580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06066580, "Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06066580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*